Sertraline use is associated with an increased risk of bleeding.
Is it true that Sertraline use is associated with an increased risk of bleeding?
Yes. Current pharmacovigilance data and clinical reviews indicate that sertraline use, particularly when combined with antiplatelet or anticoagulant medications or in elderly populations, is associated with an increased risk of bleeding events.
Verdict: SUPPORTED · 5 sources for, 1 against · Last checked
Multiple large-scale pharmacovigilance studies and reviews (such as [0], [3], [4], [5], and [7]) consistently report bleeding signals—including gastrointestinal and intracranial hemorrhage—associated with sertraline and other selective serotonin reuptake inhibitors, especially in high-risk groups or concurrent with antithrombotics. Conversely, one meta-analysis on stroke outcomes ([8]) found no significant increase in bleeding events specifically in that clinical context. Weighing the robust pharmacovigilance data and established class-wide warnings against the neutral stroke finding, the evidence clearly favors the association of sertraline use with an increased risk of bleeding.
Get citation
J, Y. & K, R. (2025). Selective Serotonin Reuptake Inhibitor-Associated Intracranial Hemorrhage: Drug-Specific Risk Patterns and Patient-Level Modifiers.. doi.org. https://doi.org/10.3390/neurolint17070111
Get citation
Y, S. & S, M. (2026). The influence of selective serotonin reuptake inhibitors on stroke outcome: a systematic review and meta-analysis.. doi.org. https://doi.org/10.3389/fneur.2026.1894976
See more details
Get citation
ACY, C. (2026). Pharmacovigilance Analysis of Bleeding Events Associated With Selective Serotonin Reuptake Inhibitors (SSRIs) Using the US Food and Drug Administration Adverse Event Reporting System (FAERS).. doi.org. https://doi.org/10.7759/cureus.110163
Get citation
Y, R., Y, Z., Y, C., & H, L. (2026). Association between concomitant use of direct oral anticoagulants with antidepressants and an increased risk of hemorrhage: analysis of the food and drug administration adverse event reporting system database.. doi.org. https://doi.org/10.3389/fmed.2026.1765791
Get citation
N, D., L, A., LC, B., RA, S., C, P., MO, B., BS, T., BȘ, P., & C, S. (2026). Prevention of Gastrointestinal Bleeding in Patients Receiving Direct Oral Anticoagulants: A Narrative Review and Practical Framework for Prescribers.. doi.org. https://doi.org/10.3390/clinpract16070120
Get citation
ACY, C. (2026). Safety Concerns, Mechanistic Pathways, and Knowledge Gaps in the Clinical Use of Selective Serotonin Reuptake Inhibitors.. doi.org. https://doi.org/10.7759/cureus.100719
What does the evidence say?
Multiple large-scale pharmacovigilance studies and reviews (such as [0], [3], [4], [5], and [7]) consistently report bleeding signals—including gastrointestinal and intracranial hemorrhage—associated with sertraline and other selective serotonin reuptake inhibitors, especially in high-risk groups or concurrent with antithrombotics. Conversely, one meta-analysis on stroke outcomes ([8]) found no significant increase in bleeding events specifically in that clinical context. Weighing the robust pharmacovigilance data and established class-wide warnings against the neutral stroke finding, the evidence clearly favors the association of sertraline use with an increased risk of bleeding.
Challenge the receipt
Citation formatting by citeproc-js (Frank Bennett) and the Citation Style Language project. Source and licenses.
Terms · Privacy · How verdicts work